MIRM vs PHAT
MIRM: Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic liver disease and viral hepatitis. PHAT: Phathom is a commercial-stage biopharmaceutical company commercializing VOQUEZNA, the first US-approved potassium-competitive acid blocker (PCAB) for gastrointestinal diseases including erosive GERD and H. pylori infection.
Side-by-side fundamentals
| Metric | MIRM | PHAT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $114.48 | $11.70 | |
| Market cap as of 2026-07-23 | $7.0B | $933M | |
| PEG as of 2026-07-23 | -0.01 | n/a | |
| Net margin as of 2026-07-23 | -140.2% | -76.8% | PHAT higher |
| Gross margin as of 2026-07-23 | +81.4% | +84.9% | PHAT higher |
| Operating margin as of 2026-07-23 | -139.8% | -47.5% | PHAT higher |
| ROE as of 2026-07-23 | -289.3% | -232.8% | PHAT higher |
| ROA as of 2026-07-23 | -98.5% | -59.7% | PHAT higher |
| Debt / equity as of 2026-07-23 | 1.28 | 12.38 | MIRM lower |
| Revenue growth (YoY) as of 2026-07-23 | +50.2% | +150.3% | PHAT higher |
| Revenue CAGR (3y) SEC XBRL | +89.1% | n/a | |
| Beta as of 2026-07-23 | 0.51 | 0.43 | |
| 1-year return as of 2026-07-22 close | +119.4% | +43.7% | MIRM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.